
- Erasca (ERAS) has surged 460% over the past year, driven by strong technical momentum.
- ERAS hit a new 3-year high of $10.92 on Monday.
- Despite bullish technicals, ERAS has no revenue, is burning cash, and its future hinges on FDA drug approvals.
- Analyst sentiment is highly speculative, with price targets ranging from $2 to $16.